Relevant Chapters

Textbook chapters most relevant to this particular component on the relevancy of cost utility and cost effectiveness as it relates to non-pharmacological or supplement treatment effectiveness in comparison to Prozac, will highlight in a balanced manner, the cost benefit of both interventions as evidenced by empirical study. Moreover, the side effects of flouxetine such as nausea, anxiety, insomnia, drowsiness, headaches, and loss of appetite should be taken into consideration when discussing the cost benefit to the client. In addition, any balanced discussion on the subject should include discourse with regard to the propensity for antidepressants to cause increased risk of suicidal ideations as compared to intervention via therapy such as rational emotive or cognitive behavioral therapy (Prigatano & Plinskin, 2003).

Summary

Flouxetine, or Prozac continues to be one of the most prescribed antidepressants for those clinically diagnosed with depression. Since its introduction some 20 years ago, Prozac has been prescribed to more than 50 million individuals in the United States and internationally. Prozac is designed to increase the supply of serotonin, a neurotransmitter, to the brain. Notwithstanding, in recent years, scientists, practitioners and scholars have posited non-pharmacological and alternative interventions to the standard of practice. Some argue that not only are non-drug related interventions as effective as pharmacological intervention, specifically Prozac, some combinations of treatment including rational emotive therapy and cognitive behavioral therapy have proven positive interventions both in therapeutic evaluation as well as cost utility and cost effectiveness.

It goes without saying that in order to adhere to the guidelines established by the APA (2002), intervention and treatment must consider all aspects of effectiveness including that of cost and benefit to the client.

Bibliography

American Psychiatric Association. (2000). APA practice guidelines for major depressive disorder (2nd ed.). Washington, DC: Author.

Antonuccio, D., Danton, W., & DeNelsky, G. (1995). Psychotherapy vs. medication for Depression: Challenging the conventional wisdom with data. Professional Psychology: Research and Practice, 6, 574-585.

(2005). Evidence of cost-effective treatments for depression: The McSad utility measure for depression health states. Journal of Affective disordersI, 84, 1-13.
Chambless, D., & Hollon, S. (1988). Defining empirically supported therapies. Journal of Consulting and Clinical Psychology, 66, 7-18.

Hunsley, J. (2003). Cost-effectiveness and medical cost offset considerations in psychological service provision. Canadian Psychology, 44, 61-73.

Olfson, M., & Klelrman, G. (1993). Trends in the prescription of anti-depressants by office-based psychiatrists. American Journal of Psychiatry, 150, 571-577.

Petersen, T., Pava, J., Buchin, J., Matthews, J., Papakostas, G., et al. (2007). The role of cognitive-behavioral therapy and flouxetine in prevention of recurrence of major depressive disorder. Cognitive Therapy Research, 34, 13-23.

Prigatano, P., Rosen, A., Herman, R., Olchanski, N., & Neumann, P. (2004). Cost-utility

Analysis studies of depression management: a systematic review. American Journal of Psychiatry, 181, 2155-2162.

Prigatano, G., & Plinskin, N. (2003). Postscript: reflections and future directions. In G.

Prigatano & N.H. Pliskin, (Eds.), Clinical neuropsychology and cost outcome research:A beginning (pp. 433-447). New York: Psychology Press.

Revicki, D., Siddique, J., Frank, L., Chung, J., Green, B., Krupnick, J., et al. (2005).

Cost effectiveness of evidence-based pharmacotherapy or cognitive behavior therapy compared with community referral for major depression in predominantly low-income minority women. Archives of General Psychiatry, 62, 868-875.

Sava, F., Yates, B., Lupu, V., Szentagotai, A., & David, D. (2009). Cost effectiveness and cost utility of cognitive therapy, rational emotive behavioral therapy, and fluoxetine in treating depression: a randomized clinical trial. Journal of Clinical Psychology, 65(1), 36-52.

Schulberg, H., Raue, P., & Rollman, B. (2002). The effectiveness of psychotherapy in treating depressive disorders in primary care practice: Clinical and cost perspectives. General Hospital Psychiatry, 24, 203-212.

Scott, J., Palmer, S., Paykel, E., Teasdale, J., & Hayhurst, H. (2003). Use of…